Diabetes CV Outcomes Trials Generate New Questions For FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee will discuss imbalances in heart failure hospitalization and all-cause mortality with AstraZeneca’s saxagliptin and subgroup differences for Takeda’s alogliptin. Even though the DPP-4 inhibitors had neutral effects overall on major adverse CV events, FDA still sees utility in long-term safety studies.